Final results of a phase I study of lapatinib (LAP) and cetuximab (CET) in patients with CET-sensitive solid tumors.
John F. Deeken
Research Funding - GlaxoSmithKline
Hongkun Wang
Research Funding - GlaxoSmithKline
John Marshall
Research Funding - GlaxoSmithKline
Deepa Suresh Subramaniam
Research Funding - GlaxoSmithKline
Jimmy J. Hwang
Research Funding - GlaxoSmithKline
Aiwu Ruth He
Research Funding - GlaxoSmithKline
Corinne Ramos
Employment or Leadership Position - Theranostics Health
Stock Ownership - Theranostics Health
Rosemarie A. Hardesty
No relevant relationships to disclose
Kenneth Steadman
No relevant relationships to disclose
Louis M. Weiner
No relevant relationships to disclose
Michael J. Pishvaian
Research Funding - GlaxoSmithKline